cyrilzakka/clinical-trials huggingface dataset:
Rationalization of the Treatment Pathway of Patient Suffering From Rare Skin Disease With Telemedicine

The investigators want to demonstrate that a new organization with telemedicine could rationalize the treatment pathway of patient suffering from rare skin disease. A diagnosis and a personalised treatment pathway could be performed before the consultation in the hospital.


Eligibility Criteria:
Inclusion Criteria:

* New patients suffering from a rare skin disease whatever pathology or age, which needs a take-over by this centre
* Or patients already take-over by the centre but lost to follow-up for more than one year
* Patients (and/or parents) who give their consents
* Patients (and/or parents) able to fill in questionnaires

Exclusion Criteria:

* Pregnant or breast-feeding women.
* Patients subject to a judicial safeguard order
* Patients who need an emergency take-over
* Patients followed by a doctor who does not have a computerized system or refuse to send data via the secured messaging
Pharmacokinetics of Aqueous Dexamethasone

The study is being done to measure the absorption of the DEXTENZA implant and inflammation concentration levels in the eye.


Eligibility Criteria:
Inclusion Criteria:

* Male of female, aged 55 or older
* Scheduled to undergo phacoemulsification with the intraocular lens (IOL) implantation for the treatment of cataract
* Willing to comply with study instructions, agree to make study appointments, and complete the course of the study
* Must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate

Exclusion Criteria:

* Known allergy or contraindication to the test article or its components
* Presence of any ocular abnormality or significant illness that, in the investigator's opinion, could affect the subject's health
* History of any illness that could be expected to interfere with the study
* Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or study
* May not be currently using topical or systemic steroids or NSAIDs during the course of the study or within 4 weeks prior to enrolling in the study other than Dextenza and Omidria
* Subject has active corneal, conjunctival, or canalicular infections, including:
* Epithelial herpes simplex keratitis (dendritic keratitis)
* Vaccini
* Varicella
* Mycobacterial infections
* Fungal diseases of the eye
* Dacryocystitis
Dress for Success: Can Just Dressing for the Gym Help Going to the Gym?

In this study, the investigators ask the question: can incentivizing smaller, less costly behaviors-like just getting yourself dressed to go to the gym-be more effective (and palatable) than incentivizing the larger goal directly?

To test this hypothesis, the investigators will randomly assign participants to one of three experimental conditions: (1) control, (2) dress for success (low effort), and (2) exercise for success (high effort). The investigators' hypothesis is that incentivizing a low effort, indirect/workout-related behavior (i.e., "dressing for success") will be more effective in motivating workouts than the control, despite a lack of economic incentive for the workout itself. Additionally, the investigators will compare workout levels for groups 2 and 3; if there is no difference between the two groups (or if 2 has higher exercise rates than 3), this would suggest that indirect incentives may be as effective as direct ones.

Eligibility Criteria:
Inclusion Criteria:

* those who opt-in to the recruitment email to all of the investigators' corporate partner's users.

Exclusion Criteria:
Computer-aided Design/Computer-aided Manufacturing for Mild to Moderate Molar Incisor Hypomineralization Treatment

Molar Incisor Hypomineralization (MIH) is a disease causing a structural defect in the enamel of permanent teeth. The treatment of these teeth consists of the removal of the affected part of the tooth and its reconstitution. Classically, the restoration is done with a resin in direct method. With the development of Computer-aided design (CAD) and Computer-aided manufacturing (CAM), it is possible to make a custom-made part to replace the affected part of the tooth. The main objective is to describe the effect of the 6-month management of CAD/CAM type restorations compared to direct restorations, performed in children aged 7 to 12 years with mild to moderate MIH on permanent molar teeth.

Molar Incisor Hypomineralization (MIH) is a structural defect of the enamel affecting at least one of the first four permanent molars. The prevalence is high, ranging from 20% to 40% of children. The consequences of MIH are multiple, including pain during food intake or an increased risk for the development of carious disease. The current standard protocol for mild to moderate MIH is the use of direct restorations (Glass Cement Ionomer type). However, this therapy is not suitable due to frequent failures. In terms of longevity, indirect restorations are superior to direct restorations. CAD/CAM in dentistry offers the possibility of making these inlay/onlay type perennial coronary restorations. It is faster to implement and does not require a conventional impression.

Eligibility Criteria:
* inclusion criteria:

  1. Child from 7 to 12 years old presenting a mild to moderate HIN on at least one permanent first molar requiring reconstitution.
  2. Child presenting a state of anxiety compatible with the provision of oral care (score on the Venham scale modified by Veerkamp below 2).
  3. Child affiliated to or benefiting from a social security scheme.
  4. Free, informed and signed consent by the parent(s)/holder(s) of parental authority and the investigator (at the latest on the day of inclusion and before any examination required by the research).
  5. Oral consent of the child.
* Non-inclusion criteria:

  1. Child presenting an allergy or a history of allergy to one of the constituents of biomaterials
  2. Child with fluorosis
  3. Child with amelogenesis imperfecta
  4. Child with pacemaker (contraindication to CAD/CAM)

     -
Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis

The purpose of this study is to compare the effect of combinative induction therapy with mitoxantrone and plasmapheresis versus induction therapy with mitoxantrone alone in cases of aggressive multiple sclerosis


Eligibility Criteria:
Inclusion Criteria:

* Aggressive multiple sclerosis in attack phase
* EDSS: 1-5
* No contraindication for mitoxantrone prescription
* No past history of mitoxantrone injection
* No history of corticosteroid and immunosuppressive therapy in last 3 months

Exclusion Criteria:

* Patient's incompliance
* Severe drug induced side effects
The Effect of Topical Tranexamic Acid on Bleeding and Seroma Formation in After Undergoing Mastectomy

After surgical procedures, interventions to reduce postoperative bleeding are of great importance. In this study, the effect will be investigated of smearing tranexamic acid, which is designed for injection, directly onto the raw wound surface (topical application) created during surgery. Topical application allows a small amount of drug to reach a large wound area, higher drug concentration in the exposed wound surface but very low concentration in the body, and no risk of injury from needles. The researchers have recently shown that topically applicated tranexamic acid reduces bleeding in women who had two-sided breast reduction surgery. Now it will be studied whether topically applicated tranexamic acid reduces bleeding after breast surgery for breast cancer.

After surgery for breast cancer patients may also experience problems with long lasting seroma. Therefore it will at the same time be investigated whether topical tranexamic acid reduces the development of seroma in these patients.


Eligibility Criteria:
Inclusion Criteria:

* breast cancer
* undergoing unilateral mastectomy with or without axillary node dissection
* received adequate oral and written information about the study and signed an informed-consent form

Exclusion Criteria:

* pregnant or breastfeeding
* known thromboembolic disease or with high risk of thromboembolism, warranting extra anticoagulation in connection with the procedure
* known allergy to tranexamic acid/Cyklokapron®
A Study for Patients With Type 2 Diabetes Mellitus

A multicenter, multinational, randomized,double-blind, placebo-controlled study in patients with Type 2 Diabetes Mellitus (T2DM). Patients with inadequate glycemic control using diet and exercise alone, or in combination with metformin, will be enrolled. The primary objective of this study is to test the hypothesis that LY2428757 given to patients with T2DM inadequately controlled with diet and exercise alone, or metformin monotherapy, produces a significant decrease in the mean hemoglobin A1c (HbA1c) from baseline to endpoint at 12 weeks as compared to placebo. Trial consists of 12 weeks of double-blind treatment and 4-week safety follow-up.


Eligibility Criteria:
Inclusion Criteria:

* Have type 2 diabetes mellitus for at least 6 months prior to entering the trial.
* Treated with diet and exercise alone or in combination with at least 1000 milligrams (mg)/day of metformin for at least 2 months prior to screening.
* Have a glycosylated fraction of hemoglobin A (HbA1c) value of 7.0% - 10.0% at screening
* Women of child-bearing potential must test negative for pregnancy at screening and agree to abstain from heterosexual intercourse for the duration of the study, or use 2 effective forms of birth control during the study.
* Have a body mass index (BMI) between 25 and 40 kilograms per square meters kg/m\^2) at screening
* Stable weight during the 3 months prior to screening.

Exclusion Criteria:

* Use any antidiabetic agent other than metformin during the 2 months prior to screening.
* Have a gastrointestinal disease that significantly impacts gastric emptying or motility or have undergone bariatric surgery.
* Are currently taking prescription or over-the counter medications to promote weight loss.
* Have been previously diagnosed with pancreatitis
* Women who are breastfeeding.
* Have a history of myocardial infarction, unstable angina, coronary artery bypass graft (CABG), percutaneous coronary intervention, transient ischemic attack, stroke or decompensated congestive heart failure in the past 6 months.
* Have poorly controlled hypertension
Comparison of I-gel LMA, Classical LMA With a New Supraglottic Airway the Baska Mask® in Urological Surgery

The most used airway management strategies are different types of supraglottic airway devices (SAD) for transurethral resection of bladder and ureteroscopy in urological surgery . Classical laryngeal mask airway (LMA-C) and I-Gel SADs are being used already. The aim of this study was to evaluate and compare the performance of a new type of SAD the Baska Mask® with I-gel and LMA-C regarding their insertion times, durations, perioperative complications and effects on hemodynamic parameters, peak airway pressures (Paw) and airway plato pressures in urological surgery as well.

The most used airway management strategies are different types of supraglottic airway devices (SAD) for transurethral resection of bladder and ureteroscopy in urological surgery . Classical laryngeal mask airway (LMA-C) and I-Gel SADs are being used already. The aim of this study was to evaluate and compare the performance of a new type of SAD the Baska Mask® with I-gel and LMA-C regarding their insertion times, durations, perioperative complications and effects on hemodynamic parameters, peak airway pressures (Paw) and airway plato pressures in urological surgery as well.

The main suggestion about the Baska Mask® is that it's the most appropriate airway device with high Paws. In high Paws, higher air leaks may occur from the sides of cuff and this causes hypoventilation. So the main aim of this study is to evaltuate three devices in terms of insertion and ventilation times, the "first attempt" success rates, the additional maneuvering requirements and complications developed after intervention.

The secondary objective of the study was to evaluate all three SADs in terms of airway pressures producing sufficient tidal volume and hemodynamical parameters.

Eligibility Criteria:
Inclusion Criteria:

* (ASA) 1-2-3 physical status scheduled for elective surgical procedure for transurethral resection of bladder and ureteroscopy.

Exclusion Criteria:

* Under the age of 18, history of hiatus hernia, gastroesophageal reflux, body mass index (BMI) \> 30 kg m-2, ASA physical status 4 or over and patients who met the difficult intubation criteria.
OSUWMC EEI Sequential Cataract Patient Experience Project

The purpose is to gauge the patients' level of comfort and anxiety for sequential cataract surgeries to assess if the second experience of cataract surgery differs from the initial experience.

Each patient is scheduled to undergo two sequential cataract extractions under topical anesthesia with local anesthetic eye drops and minimal sedation- one on each eye. The surgeon, basic surgical procedure, anesthetic technique, and approximate length of procedure are reasonably similar and the patients act as their own control. Subjects in the study will answer very brief questions regarding anxiety and comfort about their surgery before and after each procedure, and on the day after their second surgery.

Eligibility Criteria:
Inclusion Criteria:

1. Patients undergoing sequential cataract surgeries within a 6 week time period performed by the ophthalmologist, Amit Tandon, MD.
2. Aged 18 years and older.

Exclusion Criteria:

1. Cognitive impairment causing inability to participate in survey
2. Language barrier causing an inability to participate in survey
3. Healthcare POA or guardian leading to an inability to consent to survey
4. Physician autonomy; patients that are inappropriate for the study as deemed by investigator
Neurosurgery Patient Outcomes in Treating Spinal Disorders

The creation of a multi-center cooperative research group encompassing academic and community-based spinal practices . . .


Eligibility Criteria:
Inclusion Criteria:

* Grade I degenerative or isthmic spondylolisthesis recalcitrant to non-invasive therapies for at least 3 months or Lumbar degenerative disc herniation with radiculopathy refractory to non-invasive therapies for at least 6 weeks

Exclusion Criteria:

* History of previous lumbar spine surgery
* Significant motor weakness (3/5) (i.e. foot drop)
* Cancer, infection, or fracture
* Pregnancy
Safety and Efficacy of Intralesional HiLow Hyaluronic Acid in the Treatment of Peyronie's Disease (PD)

Prospective, open-label, single-arm, multicentric, pilot clinical study to confirm the safety of HiLow hyaluronic acid sodium salt for intralesional penile injection in patients affected by PD.

Prospective, open-label, single-arm, multicentric, pilot clinical study to confirm the safety of HiLow hyaluronic acid sodium salt for intralesional penile injection in patients affected by PD.

Fourty patients aged 18-75 and affected by PD in the acute phase will be enrolled in the study.

The primary endpoint is the incidence of adverse events with causal relationship during the 2.5 months of active treatment and during follow-up.

The scondary endpoint is the overall improvement of the clinical condition by evaluation of the patient's global improvement (PGI-I scale), the amelioration in the degree of the curvature of the penis and the amelioration in the length of the penis after the induction of penile erection.

Eligibility Criteria:
Inclusion Criteria:

* basal degree of penile curvature not less than 30°
* preserved erection
* documented absence of coagulation defects (at least one examination of coagulation factors within the 3 months prior to the start of the study)
* written informed consent

Exclusion Criteria:

* presence of hourglass deformity
* presence of calcified plaques
* congenital curvature of the penis
* previous penile surgery
* concomitant oral treatment for IPP
* ongoing intralesional therapy or in the 3 months prior to the start of the study
* use of any traction device
* clinically stable disease
* history of symptomatic disease \> 12 months
* known hypersensitivity or allergies to the components of the product
* any other clinical condition judged by the investigator not to be compatible with the participation in this study
Evaluation of Voice in Behcet's

Behçet's disease (BD) is a systemic inflammatory condition of unknown origin with no definite aetiopathogenetic pathways accepted worldwide. To date, only a few studies have investigated laryngeal involvement in BD and data about this are scarce. For these reasons, the present study focuses on verifying the occurrence of vocal cord involvement in patients with BD, identifying potential correlations with specific demographic, clinical, and therapeutic characteristics.

Behçet's disease (BD) is a systemic inflammatory condition of unknown origin with no definite aetiopathogenetic pathways accepted worldwide. BD owes its name to the Turkish dermatologist Hulusi Behçet, whom published in 1937 two cases of oral aphthous, genital ulcers, and recurrent uveitis with hypopion, known as triple-symptom complex. In addition to these, other clinical features encompass musculoskeletal, gastrointestinal, renal, pulmonary, cardiovascular, and cutaneous manifestations including erythema nodosum and pseudofolliculitis.To date, only a few studies have investigated laryngeal involvement in BD and data about this are scarce. For these reasons, the present study focuses on verifying the occurrence of vocal cord involvement in patients with BD, identifying potential correlations with specific demographic, clinical, and therapeutic characteristics.The study will include 60 volunteers. They will divided into 2 groups. Group I will comprise of the 30 patients with Behçet's disease (BD), and Group II will comprise of 30 controls.The inclusion criteria for selection of Group I participants will based on the criteria of the International Study Group which was proposed in 1990. The inclusion criteria for Group II will not have a Behcet's Disease.Methods

1. History taking.
2. voice sample by recording (in sustained vowel \|a\| )
3. Auditory Perceptual Assessment (APA): (Kotby et al., 1986)
4. Laryngyscopic examination:

   Patients will taken to a room with a tower on which the 8.5 mm 70 rigid laryngoscope (KARL STORZ - endoscope) (Tele pack X LED).
5. Acoustic analysis: The voice sample will be subjected to computerized acoustic analysis using Multidimensional voice program software(MDVP).

Eligibility Criteria:
Inclusion Criteria:

* The inclusion criteria for selection of Group I participants will based on the criteria of the International Study Group which was proposed in 1990. The inclusion criteria for Group II will not have a Behcet's Disease.

Exclusion Criteria:

* other autoimmune diseases.
Development of a Molecular Diagnosing Platform for Monitoring Oral Hygiene in Diabetic Patients

More than ninety percent of adults in Taiwan are suspected to carry periodontal disease, which causes bad breath, swollen and bleeding gums, plaque and even tooth loss. Half of the patients, however, are ignorance these clinical syndromes because of no obvious pain. A lot of researches show that periodontal disease is related to diabetes mellitus. Periodontal disease causes rise of blood sugar, and more than 3 times as diabetes mellitus patients as healthy people have serious periodontal disease.In this study, the investigators collect periodontal pocket and saliva samples of participants, and selecting six periodontal disease-associated bacteria strains, including Porphyromonas gingivalis (Pg), Fusobacterium nucleatum (Fn), Actinobacillus actinomycetemcomitans (Aa), Treponema denticola (Td), Prevotella intermedia (Pi) and Tannerella forsythia (Tf) as diagnostic markers. Participants will get bacteriostasis mouthwash at mouth 2. The investigators will compare the differences of blood biochemistry value and oral bacteria strains after using the mouthwash.Using real-time PCR and MALDI Biotyper, the investigators will establish the database of oral microorganisms in diabetes mellitus patients, providing periodontal disease clinical markers of high-risk groups and the basis for personal medicine of therapy in the future.


Eligibility Criteria:
Inclusion Criteria:

1. Inclusion condition of diabetes:

1. HbAlC≧6.5%
2. Glucose(AC)≧126 mg/dL
3. 2-h PG≧200mg/dL during an OGTT
4. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose≧200mg/dL 2. Inclusion condition of periodontal disease

(1) 16 natural teeths and 6 front teeth at lesat (2) Periodontal pocket≧7 mm, and radiographic bone loss≧30%

Exclusion Criteria:

1. People who have oral lesion, dental braces, denture, mouthwash allergy, or serious systemic disease
2. People who have ever eaten antibiotics and Anti-inflammatory drugs over the last 6 months
3. People who have ever eaten Immunosuppressive drugs, antiepileptic drugs, antihypertensive drugs, or anticoagulant
4. Pregnant women or the woman who eat birth control pills
Genetic Epidemiology of Venous Thromboembolism

To determine the genetic epidemiology, including genetic and environmental interactions of the multifactorial disease, venous thromboembolism (VTE).

BACKGROUND:

Venous thromboembolism is a major national health problem, with at least 201,000 first lifetime cases per year in the United States. Over 50,000 of these patients die within seven days, and for 20 percent, death is rapid, with insufficient time for medical intervention. Recurrent VTE is frequent and also associated with death as well as chronic impairment due to the venous stasis syndrome. Thus, identification of high-risk patients for targeted VTE prophylaxis or treatment is necessary to improve survival and prevent impairment. While clinical risk factors can identify a population at risk, such risk factors have low predictive value for the individual patient. The high prevalence of the Factor V R506Q (Leiden) and Prothrombin 20210G --\> A mutations among VTE patients suggests the hypothesis that additional genetic abnormalities of coagulation (thrombophilia) are associated with a substantial proportion of VTE cases.

DESIGN NARRATIVE:

The study had a case-control design. Using stored DNA samples, the investigators screened for mutations within the candidate genes for Factor V R506Q (Leiden) and Prothrombin 20210G --\> A using either dideoxy, bi-directional dideoxy, or restriction endonuclease fingerprinting, and performing population-based case-control and cohort studies using a previously identified 30-year VTE inception cohort.

The specific aims were: 1) to screen genomic DNA from patients with VTE for mutations within (candidate) genes encoding for prothrombin, thrombomodulin, tissue factor pathway inhibitor, tissue factor, factor VII, and factor X, and to determine if the mutation predicted a change in either protein expression or structure; 2) in population-based case-control studies, a) to test the hypothesis that such a mutation was associated with VTE, estimate the strength of the association, and determine the independence of the association after controlling for other environmental risk factors and coagulation abnormalities, including interactions, and b) to test the hypothesis that a mutation was associated with death and autopsy; 3) to estimate the attributable risk for VTE associated with each significant mutation, both individually and for all independently significant mutations collectively while controlling for other environmental risk factors and coagulation abnormalities; and 4) in a population-based retrospective cohort study, to estimate the time-to-VTE recurrence and to test the hypothesis that each significant mutation was an independent predictor of VTE recurrence after controlling for other environmental predictors and coagulation abnormalities, including interactions.

Eligibility Criteria:
No eligibility criteria